Therapeutic development in the absence of predictive animal models of nervous system disorders proceedings of a workshop
"Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern a...
Corporate Authors: | , , , , |
---|---|
Other Authors: | , , , |
Format: | eBook |
Language: | Inglés |
Published: |
Washington, District of Columbia :
National Academies Press
2017.
|
Edition: | 1st ed |
Subjects: | |
See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009622039306719 |
Table of Contents:
- Introduction and overview
- Drug development for nervous system disorders: overview of challenges and potential opportunities
- Case studies: therapeutic development for Parkinson's disease and schizophrenia in the absence of predictive animal models of disease
- New modeling approaches for nervous system disorders
- Private-sector thresholds for investment in neuroscience clinical trials
- Ethical considerations
- Regulatory perspectives
- Appendix A: References
- Appendix B: Workshop agenda
- Appendix C: Registered attendees.